Gasotransmitters—nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—are endogenously produced gaseous signaling molecules that play critical roles in neuronal survival, mitochondrial function, neuroinflammation modulation, and vascular regulation[1]. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), collectively termed 4R-tauopathies, dysregulation of gasotransmitter signaling contributes to disease pathogenesis through multiple mechanisms:
Therapeutic modulation of these gasotransmitter pathways offers multi-target neuroprotection in 4R-tauopathy.
Nitric oxide exhibits context-dependent effects in neurodegeneration:
| Agent | Mechanism | Stage | CBS/PSP Relevance |
|---|---|---|---|
| L-arginine | NO precursor | Research | Supports physiological NO production |
| L-NAME | nNOS/eNOS inhibitor | Research | Blocks excessive nNOS activity |
| iNOS inhibitors (1400W, L-NIL) | Selective iNOS blockade | Preclinical | Reduces microglial NO toxicity |
| NO donors (DETA-NONOate) | Controlled NO release | Preclinical | Therapeutic low-dose NO |
| PP1/PP2A activators | Dephosphorylates tau | Research | Counteracts NO-mediated tau nitration |
Carbon monoxide, produced endogenously by heme oxygenase (HO-1, HO-2), exerts neuroprotective effects through[3:1]:
| Compound | CO Release Profile | Key Features | Preclinical Data |
|---|---|---|---|
| CORM-2 (Ru(CO)3Cl2) | Fast release (min) | Metal carbonyl, photoactivatable | Neuroprotection in MPTP model |
| CORM-3 (Ru(CO)3Cl(glycinate)) | Slow release (hours) | Water-soluble, safer profile | Reduced neuroinflammation |
| CORM-371 | Controlled release | Designed for CNS delivery | Mitochondrial protection |
| MCC-494 | pH-dependent | Targeted to inflamed tissue | Anti-tau aggregation |
Hydrogen sulfide is synthesized by cystathionine beta-synthase (CBS), cystathionine gamma-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST)[4:1]. H2S exerts neuroprotective effects through:
| Compound | H2S Release Profile | Advantages | Preclinical Evidence |
|---|---|---|---|
| NaHS (sodium hydrosulfide) | Fast, transient | Well-characterized | Acute neuroprotection |
| Na2S (sodium sulfide) | Slow release | Longer duration | Mitochondrial protection |
| GYY4137 | Sustained (hours) | Orally active | Anti-inflammatory in PD models |
| AP39 | Mitochondria-targeted | Selective mtH2S delivery | Reduced oxidative stress |
| JK-1 | Slow release | Cell-permeable | Neuroprotection in tauopathy |
| S-propyl cysteine (SPC) | Endogenous precursor | Dietary source | Nrf2 activation |
The intersection of H2S and Nrf2 signaling offers particular therapeutic potential in CBS/PSP[5:1]:
Gasotransmitters exhibit synergistic interactions:
| Combination | Expected Synergy | Preclinical Evidence |
|---|---|---|
| CORM-3 + GYY4137 | Enhanced mitochondrial protection | Reduced cell death in vitro |
| NO donor + H2S donor | Anti-inflammatory + antioxidant | Improved motor function in MPTP |
| L-arginine + NaHS | NO + H2S biosynthesis precursors | Neuroprotection in stroke models |
A comprehensive approach targeting all three gasotransmitter pathways:
Indications:
Contraindications:
Phase 1: Foundation (Weeks 1-4)
Phase 2: H2S Optimization (Weeks 5-12)
Phase 3: CO Augmentation (Weeks 13-24)
Phase 4: NO Modulation (As Needed)
| Biomarker | Target | Monitoring Frequency |
|---|---|---|
| 8-OHdG (urine) | Oxidative stress | Every 8 weeks |
| NfL (plasma) | Neurodegeneration | Every 12 weeks |
| IL-6, TNF-α (CSF) | Neuroinflammation | Baseline, 24 weeks |
| Cerebral blood flow (CTP/MRI) | Perfusion | Baseline, 24 weeks |
| Domain | Score | Rationale |
|---|---|---|
| Mechanism validity | 8/10 | Strong preclinical data across NO, CO, H2S pathways |
| CBS/PSP specificity | 7/10 | Preclinical tauopathy models; no direct clinical trials |
| Evidence quality | 5/10 | Preclinical abundant; clinical translation limited |
| Safety profile | 6/10 | Generally safe with monitoring; CO toxicity risk |
| Accessibility | 4/10 | Most compounds research-grade; clinical trials needed |
| Combination potential | 8/10 | Synergistic pathways; addresses multiple mechanisms |
| TOTAL | 38/60 (63%) | Promising but requires clinical validation |
| Interaction | Mechanism | Risk Level | Management |
|---|---|---|---|
| Levodopa + NO donors | Additive vasodilation | Moderate | Monitor BP; avoid high doses |
| Rasagiline + H2S donors | Antioxidant synergy | Low | Potential benefit; monitor liver function |
| PDE5 inhibitors | Contraindicated with NO donors | High | Avoid combination |
| Antihypertensives | Additive BP lowering | Moderate | Monitor closely; adjust doses |
| SSRIs | Serotonin syndrome risk with some NO donors | Moderate | Avoid high-dose combination |
For the 50-year-old male patient with CBS/PSP:
Immediate actions:
Medium-term (3-6 months):
Long-term:
Liu Y, et al. Unraveling the potential of gasotransmitters as neurogenic and neuroprotective molecules in AD/PD. Ageing Res Rev. 2024. ↩︎
Zhang X, et al. Nitric oxide signaling in neurodegenerative diseases: therapeutic implications. Pharmacol Res. 2023. ↩︎
Motterlini R, et al. Carbon monoxide-releasing molecules: characterization and application. Antioxid Redox Signal. 2022. ↩︎ ↩︎ ↩︎
Kimura Y, et al. Hydrogen sulfide signalling in neurodegenerative diseases. Cell Mol Neurobiol. 2023. ↩︎ ↩︎
Sun Y, et al. Intersection of H2S and Nrf2 signaling: Therapeutic opportunities for neurodegenerative diseases. Free Radic Biol Med. 2024. ↩︎ ↩︎